Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Despite advances in our understanding of the pathophysiology and the management of pulmonary arterial hypertension (PAH), significant therapeutic gaps remain for this devastating disease. Yet, few innovative therapies beyond the traditional pathways of endothelial dysfunction have reached clinical trial phases in PAH. Although there are inherent limitations of the currently available models of PAH, the leaky pipeline of innovative therapies relates, in part, to flawed preclinical research methodology, including lack of rigour in trial design, incomplete invasive hemodynamic assessment, and lack of careful translational studies that replicate randomized controlled trials in humans with attention to adverse effects and benefits. Rigorous methodology should include the use of prespecified eligibility criteria, sample sizes that permit valid statistical analysis, randomization, blinded assessment of standardized outcomes, and transparent reporting of results. Better design and implementation of preclinical studies can minimize inherent flaws in the models of PAH, reduce the risk of bias, and enhance external validity and our ability to distinguish truly promising therapies form many false-positive or overstated leads. Ideally, preclinical studies should use advanced imaging, study several preclinical pulmonary hypertension models, or correlate rodent and human findings and consider the fate of the right ventricle, which is the major determinant of prognosis in human PAH. Although these principles are widely endorsed, empirical evidence suggests that such rigor is often lacking in pulmonary hypertension preclinical research. The present article discusses the pitfalls in the design of preclinical pulmonary hypertension trials and discusses opportunities to create preclinical trials with improved predictive value in guiding early-phase drug development in patients with PAH, which will need support not only from researchers, peer reviewers, and editors but also from academic institutions, funding agencies, and animal ethics authorities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
1,500 scientists lift the lid on reproducibility
Baker, M. (2016) · Nature · doi:10.1038/533452a · Cited by 4,209
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations
Greenland, S., Senn, S. J., Rothman, K. J., Carlin, J. B., Poole, C., Goodman, S. N., & Altman, D. G. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0149-3 · Cited by 3,200
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538 · cited 1×
“is associated with exaggerated estimates of intervention effects,(64) especially when the outcome of interest is subjective.(67)”
BackgroundClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888 · cited 1×
“Nonetheless, despite widespread recognition of the importance of these experimental design elements, confirmatory preclinical PH studies rarely report having implemented stringent methodologies, and their study designs have not improved during the past decade (Figure 3).(29,96,99) Furthermore, citation counts suggest…”
Background
Cited by
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
Humbert, M., Guignabert, C., Bonnet, S., Dorfmüller, P., Klinger, J. R., Nicolls, M. R., Olschewski, A. J., Pullamsetti, S. S., Schermuly, R. T., Stenmark, K. R., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01887-2018 · Cited by 1,281
Self-citationHypoxia-inducible factor signaling in pulmonary hypertension
Pullamsetti, S. S., Mamazhakypov, A., Weissmann, N., Seeger, W., & Savai, R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137558 · Cited by 234
“Head-to-head comparisons and multicenter preclinical studies of pan-HIF inhibitors and HIF-1– and HIF-2–selective inhibitors in various animal models of PH and RV dysfunction are warranted before moving into clinical development (132).”
BackgroundCellular senescence impairs the reversibility of pulmonary arterial hypertension
van der Feen, D. E., Bossers, G. P. L., Hagdorn, Q. A. J., Moonen, J.-R., Kurakula, K., Szulcek, R., Chappell, J., Vallania, F., Donato, M., Kok, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4974 · Cited by 150
“All experimental protocols were approved by the Dutch National, and Institutional Animal Care And Use Committee of the University of Groningen, Netherlands and were conducted according to published guidelines for animal and translational research in PAH (43).”
MethodBoucherat, O., Yokokawa, T., Krishna, V., Kalyana-Sundaram, S., Martineau, S., Breuils-Bonnet, S., Azhar, N., Bonilla, F., Gutstein, D., Potus, F., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00113-w · Cited by 64
Self-citation
Metadata
- Authors
- Provencher, S., Archer, S. L., Ramirez, F. D., Hibbert, B., Paulin, R., Boucherat, O., Lacasse, Y., & Bonnet, S.
- Venue
- Circulation Research
- Published
- 2018-03-30
- Volume
- 122
- Issue
- 7
- Pages
- 1021-1032
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2794636105
- Cited by
- 141
- References
- 30
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. https://app.cochat.ai/papers/10.1161/circresaha.117.312579
- The paper
- Provencher, S., Archer, S. L., Ramirez, F. D., Hibbert, B., Paulin, R., Boucherat, O., Lacasse, Y., & Bonnet, S. (2018). Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. Circulation Research. https://doi.org/10.1161/circresaha.117.312579
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.